Roche's Perjeta regimen gets FDA priority review in breast cancer
ZURICH (Reuters) - The U.S. Food and Drug Administration (FDA) has granted priority review for Roche's Perjeta in combination with Herceptin and chemotherapy for treating HER2-positive early breast cancer after surgery, Roche said on Friday.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Food and Drug Administration (FDA) | Health | HER2 | Herceptin